All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Outcomes following relapse post allo-HCT in patients with Ph+ ALL
By Ella Dixon
Bookmark this article
|
A retrospective analysis of outcomes following relapse after allogeneic hematopoietic cell transplantation (allo-HCT) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) was reported in the American Journal of Hematology. The analysis included adult patients with ALL (N = 290) who received their first allo-HCT and subsequently relapsed between 2006 and 2023 at City of Hope Hospital, Duarte, US. Morphologic relapse was defined as ≥5% bone marrow (BM) blasts, extramedullary/lymph node disease (LND), or central nervous system (CNS) involvement. Measurable residual disease (MRD) relapse was defined as ≥0.01% blasts by flow cytometry or BCR::ABL1 transcripts by PCR. |
| Key learnings |
|
The retrospective analysis showed that 2-year progression-free survival (PFS) and overall survival (OS) were:
|
|
The use of novel immunotherapies improved PFS for systemic relapses, although there was no significant difference in OS. |
|
Ponatinib was effective against resistant ABL kinase domain mutations, but no superiority was noted over older-generation tyrosine kinase inhibitors (TKIs) when used as the first TKI post-HCT relapse.
|
|
High relapse and treatment-related mortality were observed with second allo-HCT and donor lymphocyte infusions. |
|
Understanding the type of relapse (morphologic vs MRD), regular monitoring for MRD, and timely intervention with potent TKIs or immunotherapies is crucial for improving post-HCT outcomes in adult patients with Ph+ ALL. |
- Othman T, Li S, Zhang J, et al. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2024;99(8):1636-1639. DOI: 10.1002/ajh.27365
Your opinion matters
6 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox